Open access · OA
via OpenAlex
Biomarkers for Alzheimer's disease: current status and prospects for the future
Kaj Blennow, Henrik Zetterberg
Journal of Internal Medicine · 2018 · ▲ 991 citations
Abstract
Accumulating data from the clinical research support that the core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau) reflect key elements of AD pathophysiology. Importantly, a large number of clinical studies very consistently show that these biomarkers contribute with diagnostically relevant information, also in the early disease stages. Recent technical developments have made it possible to measure these biomarkers using fully automated assays with high precision and stability. Standardization efforts have given certified reference materials for CSF Aβ42, with the aim to harmonize results between assay formats that would allow for uniform global reference limits and cut-off values. These encouraging developments have led to that the core AD CSF biomarkers have a central position in the novel diagnostic criteria for the disease and in the recent National Institute on Aging and Alzheimer's Association biological definition of AD. Taken together, this progress will likely serve as the basis for a more general introduction of these diagnostic tests in clinical routine practice. However, the heterogeneity of pathology in late-onset AD calls for an expansion of the AD CSF biomarker toolbox with additional biomarkers reflecting additional aspects of AD pathophysiology. One promising candidate is the synaptic protein neurogranin that seems specific for AD and predicts future rate of cognitive deterioration. Further, recent studies bring hope for easily accessible and cost-effective screening tools in the early diagnostic evaluation of patients with cognitive problems (and suspected AD) in primary care. In this respect, technical developments with ultrasensitive immunoassays and novel mass spectrometry techniques give promise of biomarkers to monitor brain amyloidosis (the Aβ42/40 or APP669-711/Aβ42 ratios) and neurodegeneration (tau and neurofilament light proteins) in plasma samples, but future studies are warranted to validate these promising results further.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/joim.12816
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Blennow, K., & Zetterberg, H. (2018). Biomarkers for Alzheimer's disease: current status and prospects for the future. <em>Journal of Internal Medicine</em>. https://doi.org/10.1111/joim.12816
Vancouver
Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. Journal of Internal Medicine. 2018. doi:10.1111/joim.12816.
BibTeX
@article{kaj2018Biomar,
title = {Biomarkers for Alzheimer's disease: current status and prospects for the future},
author = {Kaj Blennow and Henrik Zetterberg},
journal = {Journal of Internal Medicine},
year = {2018},
doi = {10.1111/joim.12816},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Alzheimer s & Dementia 2011
Citation only
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Vanderbilt University Medical Center 2022
Open access · US-GOV
Disclosing Dementia Risk Based on Plasma Phosphorylated Tau
Alzheimer s Research & Therapy 2018
Open access · CC-BY
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
Journal of Physical Therapy Science 2016
Open access · CC-BY
Mesenchymal stem cells in regenerative rehabilitation
University Hospital, Strasbourg, France 2010
Open access · US-GOV
Analysis of Clinical Data and Diagnosis in Any Person Requiring an Assay of Alzheimer Biomarkers in Cerebrospinal Fluid
Current Alzheimer Research 2019
Citation only